View ValuationRedwood Scientific Technologies 将来の成長Future 基準チェック /06現在、 Redwood Scientific Technologiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長34.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 19Redwood Scientific Technologies Inc. Announces a Strategic Shift in its Product Development PrioritiesRedwood Scientific Technologies Inc. announced a strategic shift in its product development priorities. The New York-based firm will only focus on enhancing and expanding its nicotine replacement therapy (NRT) products, specifically TBX-FREE and TBX VAPE-FREE. This pivotal decision follows recent findings published by the American College of Cardiology, sourced from a study conducted by the National Institute of Health. The study highlights a significant correlation between e-cigarette use and an increased risk of heart failure, underscoring the urgency for effective and safe alternatives in nicotine replacement therapy. Redwood believes that its TBX-FREE and TBX VAPE-FREE products will be innovative solutions in the realm of nicotine replacement therapy. The company anticipates publication of double blind randomized studies before bringing these products to market. By concentrating its resources on TBX-FREE and TBX VAPE-FREE, Redwood is positioning itself to be at the forefront of a critical market, responding proactively to the latest scientific research and public health needs.お知らせ • Feb 07Redwood Scientific Technologies Inc. Enters into an Agreement with Jeeva Clinical Trials to Launch Clinical Effectiveness Study of its TBX-Free Oral Strips Products for Smoking and E-CortationRedwood Scientific Technologies Inc. announced that it has entered into an agreement with Jeeva Clinical Trials to launch a clinical effectiveness study of its TBX-Free oral strips products for smoking and e- vaping cessation. The company has engaged top U.S. institution, George Mason University, to conduct the efficacy study on this new product. nicotine - found in cigarettes, vapes and e- vaping - is highly addictive, acting as both a stimulant and a sedative, and has severe adverse effects on every bodily system. It has been reported that 8 million adults in the U.S. regularly use e- vaping, with 28.3 million adults who regularly use traditional cigarettes. Of this number of users, 2.5 million middle and high school students use e- vaping, with 16.5% of high school students report current use of tobacco. The CDC reported that 60% of youth tobacco users have made an attempt to quit. It has also been reported that 54% of e- vaping users have also tried to quit. Unfortunately, nicotine replacement therapies (NRTs) that are currently on the market still rely on the continued use of nicotine. These products include nicotine patches, nasal sprays, gum, and other over the counter, standard-of-care aids that are available. Redwood's TBX-free dissolvable oral strips are nicotine free and rely on the power of cytisine, a more effective active ingredient that is found in golden rain trees (Cytisus Laburnum), mainly in the seeds. Cytisine acts similarly to nicotine where it can stimulate receptors in the brain, nearly identical to e- vaping, allowing the brain to overcome the craving to vape with a lower risk of addiction.お知らせ • Nov 16Redwood Scientific Technologies Receives Conditional Approval from Irb/Cirb for Groundbreaking Clinical StudiesRedwood Scientific Technologies announced that, as of 11-13-2023 at 10:42 AM, it has secured conditional approval from the Institutional Review Board (IRB)/Central Institutional Review Board (CIRB). This milestone marks a significant advancement in Redwood's ongoing efforts towards clinical study work, aiming to develop and introduce an Oral Thin Film Strip to address nicotine addiction in vape devices. The conditional IRB approval not only paves the way for the study on Redwood's innovative product for nicotine addiction in vape devices but also extends to a study on TBX FREE, the company's primary product designed to combat nicotine addiction in traditional cigarettes. Redwood envisions being the pioneer in the market with a nicotine-free solution for addiction to nicotine in e- vape devices. This conditional approval from IRB/CIRB signifies a crucial step forward for Redwood Scientific Technologies in its commitment to addressing nicotine addiction across various mediums. The company remains dedicated to accelerating the development and market availability of these solutions to make a meaningful impact on the current challenges associated with nicotine dependency. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Redwood Scientific Technologies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:RSCI - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20120-1-1-1N/Aアナリストによる今後の成長予測収入対貯蓄率: RSCIの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: RSCIの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: RSCIの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: RSCIの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: RSCIの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RSCIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 10:11終値2026/05/04 00:00収益2012/03/31年間収益2011/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Redwood Scientific Technologies, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 19Redwood Scientific Technologies Inc. Announces a Strategic Shift in its Product Development PrioritiesRedwood Scientific Technologies Inc. announced a strategic shift in its product development priorities. The New York-based firm will only focus on enhancing and expanding its nicotine replacement therapy (NRT) products, specifically TBX-FREE and TBX VAPE-FREE. This pivotal decision follows recent findings published by the American College of Cardiology, sourced from a study conducted by the National Institute of Health. The study highlights a significant correlation between e-cigarette use and an increased risk of heart failure, underscoring the urgency for effective and safe alternatives in nicotine replacement therapy. Redwood believes that its TBX-FREE and TBX VAPE-FREE products will be innovative solutions in the realm of nicotine replacement therapy. The company anticipates publication of double blind randomized studies before bringing these products to market. By concentrating its resources on TBX-FREE and TBX VAPE-FREE, Redwood is positioning itself to be at the forefront of a critical market, responding proactively to the latest scientific research and public health needs.
お知らせ • Feb 07Redwood Scientific Technologies Inc. Enters into an Agreement with Jeeva Clinical Trials to Launch Clinical Effectiveness Study of its TBX-Free Oral Strips Products for Smoking and E-CortationRedwood Scientific Technologies Inc. announced that it has entered into an agreement with Jeeva Clinical Trials to launch a clinical effectiveness study of its TBX-Free oral strips products for smoking and e- vaping cessation. The company has engaged top U.S. institution, George Mason University, to conduct the efficacy study on this new product. nicotine - found in cigarettes, vapes and e- vaping - is highly addictive, acting as both a stimulant and a sedative, and has severe adverse effects on every bodily system. It has been reported that 8 million adults in the U.S. regularly use e- vaping, with 28.3 million adults who regularly use traditional cigarettes. Of this number of users, 2.5 million middle and high school students use e- vaping, with 16.5% of high school students report current use of tobacco. The CDC reported that 60% of youth tobacco users have made an attempt to quit. It has also been reported that 54% of e- vaping users have also tried to quit. Unfortunately, nicotine replacement therapies (NRTs) that are currently on the market still rely on the continued use of nicotine. These products include nicotine patches, nasal sprays, gum, and other over the counter, standard-of-care aids that are available. Redwood's TBX-free dissolvable oral strips are nicotine free and rely on the power of cytisine, a more effective active ingredient that is found in golden rain trees (Cytisus Laburnum), mainly in the seeds. Cytisine acts similarly to nicotine where it can stimulate receptors in the brain, nearly identical to e- vaping, allowing the brain to overcome the craving to vape with a lower risk of addiction.
お知らせ • Nov 16Redwood Scientific Technologies Receives Conditional Approval from Irb/Cirb for Groundbreaking Clinical StudiesRedwood Scientific Technologies announced that, as of 11-13-2023 at 10:42 AM, it has secured conditional approval from the Institutional Review Board (IRB)/Central Institutional Review Board (CIRB). This milestone marks a significant advancement in Redwood's ongoing efforts towards clinical study work, aiming to develop and introduce an Oral Thin Film Strip to address nicotine addiction in vape devices. The conditional IRB approval not only paves the way for the study on Redwood's innovative product for nicotine addiction in vape devices but also extends to a study on TBX FREE, the company's primary product designed to combat nicotine addiction in traditional cigarettes. Redwood envisions being the pioneer in the market with a nicotine-free solution for addiction to nicotine in e- vape devices. This conditional approval from IRB/CIRB signifies a crucial step forward for Redwood Scientific Technologies in its commitment to addressing nicotine addiction across various mediums. The company remains dedicated to accelerating the development and market availability of these solutions to make a meaningful impact on the current challenges associated with nicotine dependency.